Efficacy of Pomalidomide in HHT-related bleeding

泊马度胺治疗 HHT 相关出血的疗效

• 批准号: 8914664
• 负责人: Keith R. McCrae
• 金额: $ 23.66万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-08-19 至 2017-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8914664
• 关键词: Address; Affect; Angiodysplasia; Arteriovenous malformation; Biological Markers; Blood Vessels; Brain; Cancer Patient; Cauterization - action; Chronic; Clinical; Clinical Investigator; Clinical Trials; Dependence; Disease; Elements; Eligibility Determination; Endothelial Cells; Enrollment; Epistaxis; Fibrinolytic Agents; Funding; Generations; Generic Drugs; Goals; Health; Hemorrhage; Hemostatic Agents; Hereditary hemorrhagic telangiectasia; Hypertension; Incidence; Industry; Inherited; Intestines; Intravenous infusion procedures; Iron; Lead; Legal patent; Light Coagulation; Liver; Lung; Manufacturer Name; Measures; Membrane; Multiple Myeloma; Mutation; New Agents; Nose; Octreotide; Organ; Pathogenesis; Patients; Perforation; Phase III Clinical Trials; Pilot Projects; Placebo Control; Plasma; Play; Population; Proteins; Quality of life; Randomized; Recurrence; Regulation; Reporting; Resistance; Resource Development; Resources; Role; Rupture; Safety; Signal Pathway; Small Intestines; Supporting Cell; Surface; Symptoms; Thalidomide; Thrombosis; Tissues; Toxic effect; Transfusion; Work; abstracting; analog; angiogenesis; bevacizumab; bone morphogenic protein; design; effective therapy; experience; gastrointestinal; hormone therapy; impression; improved; innovation; interest; novel; phase 3 study; phase III trial; prevent; protocol development; randomized placebo controlled trial; repository; response; symptom management

DESCRIPTION (provided by applicant): Hereditary Hemorrhagic Telangiectasia (HHT) is a rare, inherited bleeding disorder caused by mutations in Eng, ALK1 or Smad4. The pathogenesis of HHT involves formation of arteriovenous malformations (AVM) in several tissues and organs including the brain, lung, liver and mucosal membranes. These fragile AVMs are highly prone to bleeding. Of the many clinical manifestations of HHT, recurrent epistaxis and gastrointestinal (small bowel) bleeding are most common; bleeding is chronic, leads to dependence on transfusion and parenteral iron, and significantly impairs quality of life. Treatment for the bleeding manifestations of HHT is supportive, since no effective, non-toxic therapy that causes consistent regression of AVMs has been convincingly demonstrated. The PI's experience with four patients with severe gastrointestinal bleeding from small bowel AVMs, as well as numerous anecdotal reports, suggests that thalidomide causes regression of AVMs and arrests bleeding in patients with HHT. However, thalidomide is not patent protected, is not supplied by the manufacturer for clinical trials and is not produced by manufacturers of generics. Therefore, we propose to design a phase III trial of pomalidomide, a third generation thalidomide analogue with greater anti-angiogenic activity and an improved safety profile, in patients with HHT-related bleeding. We expect to demonstrate feasibility for this trial and activit of pomalidomide for this indication in a 15 patient, industry- funded pilot study in which all patients will be enrolled prior to initiation of this U34. We have assembled a multi-disciplinary, multi-institutional protocol development team that will work with the U24 Clinical Trials Resource to plan the study. Goals of this proposal are 1) To develop a randomized, placebo-controlled phase III study to assess the efficacy and safety of pomalidomide in HHT-related epistaxis and/or gastrointestinal bleeding, and 2) To plan a repository of blood and plasma fractions obtained from patients with HHT before and during pomalidomide therapy that will be used for defining biomarkers of response to pomalidomide and other agents. This proposal utilizes innovative planning strategies to develop a clinical trial of a novel agent that may lead to a new paradigm for treatment of bleeding in patients with HHT.

描述（由申请人提供）：遗传性出血性毛细血管扩张症（HHT）是一种罕见的遗传性出血性疾病，由Eng、ALK 1或Smad 4突变引起。HHT的发病机制涉及在包括脑、肺、肝和粘膜在内的几种组织和器官中形成动静脉畸形（AVM）。这些脆弱的动静脉畸形极易出血。在HHT的许多临床表现中，复发性鼻出血和胃肠道（小肠）出血是最常见的;出血是慢性的，导致对输血和肠外铁剂的依赖，并显著损害生活质量。HHT出血表现的治疗是支持性的，因为没有令人信服地证明有效、无毒的治疗可导致AVM持续消退。PI在4例小肠AVM导致重度胃肠道出血患者中的经验以及大量轶事报告表明，沙利度胺可导致AVM消退并阻止HHT患者出血。然而，沙利度胺不受专利保护，不是由制造商提供用于临床试验，也不是由仿制药制造商生产的。因此，我们建议在HHT相关出血患者中设计一项泊马度胺III期试验，泊马度胺是第三代沙利度胺类似物，具有更强的抗血管生成活性和更好的安全性。我们预计将在一项包含15名患者、行业资助的试点研究中证明这项试验的可行性以及泊马度胺对该适应症的活性，所有患者将在这项U34开始之前入组。我们已经组建了一个多学科，多机构的方案开发团队，将与U24临床试验资源合作规划研究。本提案的目标是：1）开展一项随机、安慰剂对照的III期研究，以评估泊马度胺在HHT相关鼻出血和/或胃肠道出血中的疗效和安全性; 2）计划建立一个泊马度胺治疗前和治疗期间从HHT患者中获得的血液和血浆组分库，用于定义泊马度胺和其他药物反应的生物标志物。该提案利用创新的规划策略来开发一种新型药物的临床试验，这可能会导致HHT患者出血治疗的新范式。